Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Neuren Pharmaceuticals Limited ( (AU:NEU) ) is now available.
Neuren Pharmaceuticals Limited announced an update regarding its ongoing on-market buy-back of ordinary fully paid securities. As of May 21, 2025, the company has bought back a total of 3,456,734 securities, with 21,276 securities repurchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$30.65 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurological disorders. The company is listed on the Australian Securities Exchange under the code NEU.
Average Trading Volume: 786,902
Technical Sentiment Signal: Hold
Current Market Cap: A$1.61B
For an in-depth examination of NEU stock, go to TipRanks’ Stock Analysis page.